Enterprise Value
3.896M
Cash
41.77M
Avg Qtr Burn
-20.52M
Short % of Float
2.37%
Insider Ownership
22.61%
Institutional Own.
47.82%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMT-101 (IL-10 oral agonist) Details Pouchitis | Phase 3 Initiation | |
AMT-101 (IL-10 oral agonist) +anti-TNFα Details UC (Ulcerative colitis) | Phase 2 Data readout | |
AMT-101 (IL-10 oral agonist) Details Ulcerative colitis | Phase 2 Data readout | |
AMT-101 (IL-10 oral agonist) +anti-TNFα Details RA (rheumatoid arthritis) | Phase 2 Data readout | |
AMT-126 (IL-22) Details GI barrier repair | Phase 1b Update |